奥浦迈：资产过户手续完成 澎立生物成为公司全资子公司

Group 1 - The core point of the article is that Aopumai Biotech has officially acquired 100% of the shares of Plenitude Biopharmaceutical Technology, making it a wholly-owned subsidiary [2] - The acquisition was completed through a combination of issuing shares and cash payment, with a total transaction price of 1.451 billion yuan [2] - The acquisition has been approved by the Shanghai Stock Exchange's M&A Review Committee on December 9, 2025, and involves 31 transaction parties [3] Group 2 - Aopumai plans to use differentiated pricing strategies, including installment payments in stock and cash, to complete the acquisition [3] - The original financial investors of Plenitude Biopharmaceutical will bear part of the performance compensation responsibility [3] - This acquisition is notable as it is the first project in the A-share market to adopt a phased payment mechanism for restructuring shares since the release of the "Six Mergers" policy [3]